pharmaphorum January 21, 2025
Phil Taylor

Odyssey Therapeutics and Sionna Therapeutics have filed to carry out initial public offerings (IPOs) on the Nasdaq, taking the number in the newly-filed queue to four since the start of the year.

The two filings – both for companies based in Massachusetts and reported by Renaissance Capital – have the usual $100 million placeholder value, but both the number of shares on offer and their price range remain confidential for now.

Odyssey is a specialist in autoimmune and inflammatory diseases. In its provisional prospectus, the start-up says the proceeds of the IPO will go towards phase 2a trials of OD-07656, its small molecule RIPK2 inhibitor. To date, most effort by the pharma industry in this area has focused on RIPK1,...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
mRNA Vaccine Shows Promise In Pancreatic Cancer Trial
Hims & Hers vs. Novo Nordisk: Are Compounded GLP-1s Safe?
On Heels of FDA Nod, BridgeBio’s Rival to Blockbuster Pfizer Drug Wins European Approval
The First Diagnostic Immunome
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity

Share This Article